Does a decrease in forced expiratory volume in one second (FEV1) from 102 % of predicted to 82 % of predicted after administration of albuterol (salbutamol) indicate that albuterol is ineffective for this patient?

A Decrease in FEV1 After Albuterol Does NOT Mean the Drug is Ineffective

A decrease in FEV1 from 102% to 82% after albuterol is highly unusual and does NOT represent a typical lack of response—this is a paradoxical bronchodilator response that requires immediate clinical reassessment. This 20% decline is not simply "no response"; it represents actual worsening that demands investigation.

Understanding Normal Bronchodilator Response

Albuterol typically produces measurable improvement in FEV1 within 5 minutes, with maximum effect at approximately 1 hour 1. The expected response varies by patient population:

• In asthma patients: Mean improvement of 14.4% in percentage predicted FEV1 over baseline (though this varies from 11.7% in African American patients to 17.5% in white patients) 2
• In COPD patients: Responses are smaller and more variable, with mean improvements of 160±170 mL in GOLD grade 2, decreasing to 50±80 mL in GOLD grade 4 3

Why This Case is Concerning

The 20-percentage-point drop you describe is a paradoxical response, not simply "non-response." This phenomenon, while rare, is documented in the literature 4. Key considerations:

Paradoxical Bronchodilator Response

• Some patients experience actual bronchoconstriction with short-acting beta-2 agonists (SABAs)
• This manifests as decreased FEV1 rather than improvement
• These patients may respond to alternative bronchodilators like anticholinergics (ipratropium bromide) 4

Technical and Measurement Issues to Rule Out

Before concluding this is a true paradoxical response, verify:

• Spirometry technique quality: Was the post-bronchodilator test performed correctly with adequate effort?
• Timing: Was the measurement taken at the appropriate time (15-20 minutes post-administration)?
• Baseline variability: FEV1 can vary considerably test-to-test even in the same patient 3

Clinical Significance Beyond FEV1

Critically important: Bronchodilators can be effective even without FEV1 improvement 3. The evidence shows:

• Volume responses matter: Bronchodilators reduce end-expiratory lung volumes and improve inspiratory capacity, which decreases work of breathing and improves exercise tolerance 3
• In one study, 23% of COPD patients showed volume responses (FVC improvement) without flow responses (FEV1 improvement) 3
• Symptom improvement can occur without FEV1 changes: Patients may experience reduced dyspnea and improved quality of life through mechanisms not captured by FEV1 3

Recommended Clinical Approach

For this specific patient with declining FEV1:

1. Repeat spirometry to confirm the finding and rule out technical error
2. Assess FVC response: Check if FVC improved even though FEV1 declined—this would indicate volume response
3. Evaluate symptoms: Does the patient feel better or worse after albuterol?
4. Consider paradoxical response: If confirmed, trial anticholinergic bronchodilators (ipratropium) as alternative 4
5. Review diagnosis: A starting FEV1 of 102% predicted suggests this may not be typical obstructive disease; consider alternative diagnoses

Common Pitfalls to Avoid

• Don't assume albuterol "doesn't work" based solely on FEV1: Check FVC, symptoms, and exercise tolerance
• Don't ignore a declining FEV1: This is different from "no response" and requires investigation
• Don't continue albuterol if paradoxical response confirmed: Switch to alternative bronchodilator classes
• Don't overlook measurement error: Repeat testing is essential when results are unexpected

In summary: A 20% decline in FEV1 after albuterol is not a simple "non-response"—it's either a measurement error requiring verification or a true paradoxical response requiring medication change. The patient's clinical symptoms and alternative spirometry parameters (particularly FVC) must guide management decisions.